By inhibiting neprilysin, increasing levels of vasoactive peptides, and promoting smooth muscle relaxation, SV may alleviate digital ischemia in RP and reduce pulmonary vascular resistance in PAH, potentially offering a therapeutic advantage in these SSc complications. Here, MME is linked to pulmonary arterial hypertension.